Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

Video

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study will impact testing going forward.

Updated results from the KEYNOTE-799 study, presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) Singapore, revealed pembrolizumab (Keytruda) plus concurrent chemoradiation therapy may be effective for treating patients with unresectable, locally advanced, stage III non–small cell lung cancer (NSCLC).

In an interview with CancerNetwork®, Salma Jabbour, MD, chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey, explained how the results of the ongoing study may guide testing moving forward.

Transcription:

The results of this study will hopefully help to guide phase 3 testing, which is currently ongoing in KEYLYNK-012 (NCT04380636). [This study] will look at the earlier incorporation of pembrolizumab with concurrent chemo-radiotherapy and will compare it to the standard of care, which is to receive immunotherapy after the completion of chemo-radiotherapy for stage III non–small cell lung cancer. It will be very exciting to see what these results will be and how they may change or improve our practice going forward to help patients.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content